Novo Nordisk to launch new slimming drug

Pharma group targets $1bn in annual revenues from Saxenda

GSK ships Ebola vaccine to west Africa

Drugmakers race to launch trials amid decline in new cases

Sanofi’s ousted CEO Viehbacher received €3m pay-off

French pharma group reveals deal as it seeks for successor

US investors double down on biotech bets

Sector adds to 2014 gains, bucking wider January sell-off

‘A bit of luck’ halted Ebola, says Gates

Billionaire philanthropist says world must react faster next time

Hungry Actavis pauses to digest Allergan

Pharma dealmaker still talking to ‘dozens’ of potential targets

Valeant admits Allergan ‘miscalculation’

Pearson reflects on tussle and what went wrong with failed bid

Actavis lab Handout from Elisabet Hjaltadottir Executive Director Corporate Communications Actavis Turmstrasse 24, CH-6300 Zug Switzerland T: +41 41 462 7300 D: +41 41 462 7370 M: +41 79 909 7370 e: elisabet.hjaltadottir@actavis.com www.actavis.com

Actavis and Valeant eye more deals

Enthusiasm could herald further healthcare consolidation

Hepatitis C Virus

Gilead and AbbVie step up hepatitis C fight

Competition will be welcomed by public health systems in Europe

Sacking boss no panacea for share price woes

A board acting at first whiff of trouble can do real harm, writes Jonathan Ford

UK looks to raise its game in robotics

Companies rush to compete for share of market for robot systems

Small-cap Week, January 17

Kenmare, DCD Media, Animalcare and Kromek featured

Week in Review, January 17

Car party in Detroit; MetLife, oil projects, and drug deals also in the news

J&J receives €100m EU boost for Ebola

US healthcare group’s treatment boosted amid race to start trials

China reports sharp rise in HIV cases

New infections increased 15% to 100,000 in 2014

Labour sugar clamp gets frosty reception

Industry brands anti-obesity plan paternalistic and unworkable

Healthcare: Counting the cost of cancer

The cost of new drugs is pushing health budgets to the limit

India rejects Gilead patent application

Refusal looks set to prompt cheap generic versions of Sovaldi

Doctor links A&E chaos to NHS advice line

Of 446,000 rise in cases, almost all were sent by 111 service

AstraZeneca gets fillip from drug data

Study could lead to broader use of blood-thinning treatment

COMPANIES NEWS ON TWITTER

More FT Twitter accounts
SHARE THIS QUOTE